SupplyManager℠  Become a Customer

  • #1087941
  • 3,159
  • Seqirus USA Inc #33332031801
Afluria® Quadrivalent 2018 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 3 Years of Age and Above Prefilled Syringe 0.5 mL

Features
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 3 Years of age and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2017-2018 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2017-2018 Northern Hemisphere influenza season: A/Singapore/GP1908/2015 (H1N1), IVR-180A, A/Hong Kong/4801/2014 (H3N2), NYMC X-263B, B/Phuket/3073/2013 BVR-1B and B/Brisbane/46/2015
  • More …
  Log In to Order
or

Professionals Also Viewed


Product Specifications


McKesson #1087941
Manufacturer #33332031801
BrandAfluria® Quadrivalent 2018
ManufacturerSeqirus USA Inc
ApplicationFlu Vaccine
Container TypePrefilled Syringe
Dosage FormInjection
NDC Number33332031801
Storage RequirementsRequires Refrigeration
Strength60 mcg / 0.5 mL
TypeIntramuscular
UNSPSC Code51201608
UserIndicated For People 3 Years of Age and Above
Volume0.5 mL
Features
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 3 Years of age and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2017-2018 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2017-2018 Northern Hemisphere influenza season: A/Singapore/GP1908/2015 (H1N1), IVR-180A, A/Hong Kong/4801/2014 (H3N2), NYMC X-263B, B/Phuket/3073/2013 BVR-1B and B/Brisbane/46/2015